Moderna awaits a crucial decision from the Food and Drug Administration (FDA) regarding its mRNA-based flu shot. This decision holds significant weight for the trajectory of mRNA research.
Stephen Hoge, Moderna’s president, recalled being informed of a serious issue when Charbel Haber, the head of regulatory affairs, approached him. The concern stemmed from a letter indicating the FDA’s refusal to review Moderna’s application for the mRNA flu shot. This development was unexpected, given ongoing discussions with the FDA, which had previously indicated support for the submission.
The FDA’s initial rejection caused considerable upheaval in the pharmaceutical industry. Public reaction was swift, leading to the FDA reconsidering and eventually agreeing to review the vaccine. Moderna resolved to conduct a confirmatory study if the vaccine advances to market. An FDA advisory panel recommended approval in June, setting a deadline for a final decision.
If approved, Moderna’s flu shot would be the pioneering mRNA-based vaccine for influenza. However, the FDA’s early decision had repercussions, stoking uncertainty in the market. Rena Conti, a health economist at Boston University, highlighted concerns about the market’s reaction to regulatory consistency. Investors need assurances of market feasibility to justify significant investments.
The Department of Health and Human Services (HHS) further exacerbated uncertainties by canceling $500 million in mRNA research funding. Responses to inquiries stressed HHS’s commitment to robust, evidence-based public health regulations.
Jeff Coller of Johns Hopkins University noted the ripple effect on smaller biotech companies, which depend on venture capital. The FDA’s rejection of Moderna’s application alarmed these firms, hindering investment in diverse mRNA applications, from Lyme disease to cancer treatments.
An example of mRNA innovation’s impact is Janusz Racz, a retired scientist living in London. Diagnosed with inoperable lung cancer, Racz became part of a clinical trial for a BioNTech mRNA vaccine. Remarkably, after regular vaccinations, his cancer vanished. Despite this success, Racz criticized the Trump administration and health officials for diminishing mRNA research prospects through funding cuts.
Racz, a U.S. citizen, wrote to Health Secretary Robert F. Kennedy Jr., sharing his recovery story and urging sustained support for mRNA advances. However, he never received a response.